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Abstract Epidermal growth factor receptors (EGFR) are
associated with a number of biological processes and are
becoming increasingly recognized as important therapeutic
targets against cancer. In this work, we provide models
based on homology for the extracellular domains (ECD) of
ErbB3 and ErbB4 in their active conformations, including a
Heregulin ligand, followed by further refinement of the
models by molecular dynamics simulations at atomistic
scale. We compare the results with a model built for ErbB2
based on crystallographic information and analyze the com-
mon features observed among members of the family, name-
ly, the periscope movement of the dimerization arm and the
hinge displacement of domain IV. Finally, we refine a model
for the interaction of the ECDs corresponding to a ErbB2–
ErbB3 heterodimer, which is widely recognized to have a
high impact in cancer development.
Keywords EGFR receptors . Homology modeling .
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Introduction
Epidermal growth factor receptors (EGFR) control multiple
cellular processes, including cellular proliferation, survival,
differentiation and migration [1]. The EGFR family consists
of four different members: EGFR/ErbB1, ErbB2, ErbB3 and
ErbB4. These receptors are formed by three differentiated
regions: an extracellular ligand-binding domain (ECD) con-
taining four sub-domains (I–IV), a single transmembrane α-
helix (TMH) spanning the cellular membrane and intracel-
lular juxtamembrane, tyrosine-kinase and autophosphoryla-
tion domains. It is well established that epidermal growth
factors (EGF) bind to the ECD domain, promoting EGFR
dimerization and increasing the tyrosine-kinase activity of
its intracellular domain.
The orientation of the four ECD sub-domains has been
revealed by recent crystallographic studies. On the basis of
these studies, tethered (ErbB3 [2], ErbB1/EGF [3], ErbB1/
Cetuximab [4],ErbB4 [5]) and extended (EGF-bound [6] and
TGFα-bound [7] truncated ErbB1 dimers, trastuzumab [8]
and pertuzumab [9] ErbB2 complexes and full EGF-bound
ErBB1 dimer [10]) conformations have been proposed for
ECD-EGFR receptors. The tethered or autoinhibited confor-
mation ties domains II and IV, forming intramolecular inter-
actions. Accordingly, the dimerization arm in domain II is
buried by domain IV, impairing the formation of EGFR
dimers. On the contrary, interactions between domains II and
IV are broken in the active untethered or extended conforma-
tion, provoking a release of the dimerization arm, which can
now dimerize with other EGFR monomers.
The ECD of ErbB1, ErbB3, ErbB4 contains a specific
region that binds EGF. This binding is thought to promote
intracellular signaling cascades that regulate cellular growth
and proliferation. Ligand binding promotes signaling acti-
vation by homo- or hetero-dimerization in the membrane
surface, changing the receptor conformation from a tethered
structure to an extended dimerization-exposed arm confor-
mation [11]. Other authors, however, claim that the ligand
can alter the equilibrium between previously formed active/
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inactive dimers [11, 12]. Unlike other members of the fam-
ily, the ErbB2 receptor can adopt a fixed conformation
(extended conformation) resembling the ligand-activated
state, which is able to dimerize even in the absence of ligand
[13]. These receptors are engaged in the regulation of many
processes such as cell proliferation, differentiation and apo-
ptosis. The abnormal regulation of these receptors generates
a number of human diseases, such as cancer [1, 14].
As mentioned above, crystal structures for the extended
configurations of ErbB1 [6, 7] and ErbB2 [8, 9] are avail-
able. Additionally, homology structures for ErbB3 and
ErbB4 have been built using as template the crystal structure
of 2:2 EGF:EGFR complex (PDB code: 1IVO) [15]. Note
that this template lacks the disordered domain IV, and ho-
mology structures can be obtained without this critical do-
main. It is only recently that the crystal structure of the 2:2
EFG:EGFR dimer containing domain IV has been reported
[10]. Therefore, we propose to use this structure as a tem-
plate to model a more complete structure of the ErbB3 and
ErbB4 receptors.
The biological activity of these receptors is known to
depend on the formation of homo or heterodimers in such
a way that the intracellular kinase domains in close contact
can interact, initiating a signaling cascade that ends with
cellular proliferation [16]. The complex formed by ErbB2
and ErbB3 has been recognized as being of pivotal impor-
tance in cancer development and evolution [17].
Considering some theoretical work concerning ECDs,
Fuentes et al. [18] have carried out several molecular dy-
namics (MD) studies on ErbB2 along with two different
antibodies, trastuzumab (Tzb) and pertuzumab. They esti-
mated the binding free energy for several receptor/antibody
complexes. They reported that trastuzumab has a higher
affinity for apo ErbB2 than pertuzumab. Furthermore, the
epitope for trastuzumab is domain IV whereas pertuzumab
is bound to the dimerization arm located in domain II.
Subsequently, they found an increase in affinity when both
antibodies are bound to the receptor.
On the other hand, Du et al. [19] performed micro-
second MD simulations of ErbB4 tethered with its en-
dogenous ligand neuregulin1β (NRG1β). While the
conformational transition of the ECR-ErbB4/NRG1β
complex from a tethered inactive conformation to an
extended active-like form is observed clearly in the sim-
ulation, the conformational change of ECR-ErbB4 is not.
Therefore, it could be proposed that ligand binding is
indeed the active driving force for the conformational
transition and further dimerization to occur. These
authors constructed an energy landscape for the confor-
mational transition of ECR-ErbB4/NRG1β complex and
reported that the energy barrier for the tether opening has
a value of 2.7 kcal/mol, which is close to the experi-
mental value (1–2 kcal/mol) reported for ErbB1.
Additionally, Bagossi et al. [20] reported the first ErbB2/
Tzb:ErbB2/Tzb complex from homology based on the X-ray
or nuclear magnetic resonance structures of extracellular,
transmembrane, and intracellular domains. They predicted
some favourable dimerization interactions for the extracellu-
lar, transmembrane, and protein kinase domains in the model
of a nearly full-length dimer of ErbB2, which may act in a
coordinated fashion in ErbB2 homodimerization.
The objective of the present study was to build homology
models of the ECDs corresponding to ErbB3 and ErbB4
receptors in their extended conformations along with a model
of the back-to-back ErbB2/ErbB3:HRG-α heterodimer.
Water-equilibrated models of the ErbB2, HRG-α:ErbB3
and HRG-α:ErbB4 complexes were built using as templates
the X-ray crystal structure of the ErbB2/Tzb (PDB code:
1NZ8) and 2:2 EFG:EFGR dimer (PDB code: 3NJP) com-
plexes, respectively, as starting structures, due to the high
homology of this receptor family. MD simulations (100 ns)
were performed and details of the interactions and intrinsic
motions were investigated for each model through principal
component analysis (PCA). Additionally, a homology struc-
ture of the ECDs of the back-to-back ErbB2:ErbB3: HRG-α
complex were built and refined through multi-nanosecond
MD simulation. To our best of our knowledge, this is the
first computational model of this important complex.
Computational methods
Homology models for the ECD of HRG-α:ErbB3, HRG-α:
ErbB4 and back-to-back ErbB2:ErbB3:HRG-α complexes
The amino acid sequences of HRG-α, ErbB3 and ErbB4
were obtained from the SwissProt database (P04626,
P21860,Q15303). Homology models of the HRG-α:ErbB3
and HRG-α:ErbB4 complexes were built using as a tem-
plate the X-ray crystal structure of chain A of the 2:2 EFG:
EGFR dimer (PDB code: 3NJP) [10]. Unlike the published
homology models for HRG-α:ErbB3 and HRG-α:ErbB4
based on the 1IVO structure [15], our template allows the
region of domain IV to be included in the homology model.
The importance of the orientation of this tight domain has
been recognized because of the dependence of intracellular
protein kinase domain orientation on domain IV disposition
[6, 7].
All models were generated using the PRIME application
of the Schrödinger Suite 2011 (Schrödinger, New York,
NY). First, pairwise sequence alignments between ErbB3
and ErbB4 and the EFGR template sequences were per-
formed. The BLAST alignment gives 61 % and 63 % of
positives (percentage of residues that are positive matches to
the BLOSUM62 similarity matrix [21]) and 46 % and 47 %
of identities (percentage of residues that are identical
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between sequences) using 1 % and 1 % of gaps between the
template and ErbB3 and ErbB4, respectively. However, this
simple alignment does not assign adequately the secondary
structure between the template and the query, as predicted by
SSpro program [22] . For this reason, we adopted an align-
ment algorithm (single template algorithm, STA) that takes
into account both secondary structure matching and profile-
sequence matching. This procedure minimizes the inaccuracy
in a single secondary structure prediction at the expense of
increasing the percentage of gaps. This algorithm was
designed specially for protein sequences with medium-to-
high sequence identity (>25 %). The 3D-structures were built
by replicating the backbone atom coordinates for the aligned
regions and side chains of conserved residues, followed by
optimization of the side chains and non-template residues.
Finally, the gaps were filled by insertions and final closing
of deletions in the alignment. In all cases, the gap length was
less than 15. Finally, the homology model coordinates were
minimized with Schrödinger [23] using OPLS-2005 with the
default threshold of 0.05 kJ/mol as the convergence criteria.
The same procedure was used for the homology model of
the HRG-α peptide ligand taking as template the EGF peptide
of the 3NJP structure. The final HRG-α:ErbB3 and HRG-α:
ErbB4 models were built using both sets of coordinates, i.e.,
receptor and ligand moieties, respectively.
Model of the ErbB2 receptor
The initial model of the ErbB2 ectodomain was extracted
directly from the 3-D crystal structure deposited with the
Protein Data Bank server (PDB code: 1N8Z) [8]. The miss-
ing residues N124–A132 (domain I), E325–G327 (domain II),
G383–G386 (domain III) and G603–P612 (domain IV) were
modeled based on homologous sequences using the PRO-
DAT database implemented in Sybyl 8.0 [24]. The loop
fragment that affords the best geometric fit as monitored by
the homology score and RMS fit, was incorporated automat-
ically into the model [24, 25] . The side chains were built
using the rotamer library of Sybyl by taking a scan angle of
30° and a VDW factor of 0.9. The selected side-chain con-
formation is the one that presents the fewest bumps on the
rest of the molecule. Finally, the structure was relaxed over
2,500 steps using the steepest descent minimization algo-
rithm as implemented in GROMACS 4.5.3 [26]
We assume that the pKa of the individual amino acid
residues at physiological pH does not change when they are
assembled into the protein receptor. Thus, histidine (H)
residues were kept neutral while lysine (L) and arginine
(R) were protonated and aspartic (D) and glutamic (E) acids
were deprotonated.
The resulting total charge for the complex was −10 e. The
system was then solvated by adding 60,717 water molecules
and 10 Na+ ions to yield an electrically neutral system. The
system was finally equilibrated in a 2 ns NPT-MD simula-
tion with position restraint for all protein atoms.
Molecular dynamics
The OPLS force field [27–29] for protein and SPC model
[30] for water were used throughout this work. Short-range
repulsion-dispersion interactions were truncated smoothly at
10 Å. The particle mesh Ewald (PME) method [31, 32] was
used to calculate long-range electrostatic interactions, by
means of a maximum grid spacing of 2.5 Å and using
fourth-order (cubic) interpolation for the fast Fourier trans-
forms. The temperature was kept constant at 300 K by
coupling the protein, the ions and the solvent independently
to an external bath using the Berendsen algorithm [33] with
a coupling constant of 0.2 ps.
We used isotropic scaling for the pressure (1 bar) and a
coupling constant of 1.0 ps and a compressibility of 4.5×
10−5bar−1 when applying the Berendsen algorithm [33]. The
dynamics were integrated using the velocity Verlet integra-
tor, with a time step of 2 fs and bonds constrained using the
LINCS algorithm [34].
Production dynamics was performed at constant pressure
and temperature (NPT ensemble) releasing all constraints on
the heavy atoms during 100 ns, and storing the trajectory every
10 ps. All minimizations, restrained and unrestrained MD runs
were performed with GROMACS 4.5.3 [26]. Molecular
graphics were drawn using the VMD 1.8.7 package [35].
PCA, hydrogen bonds and contact maps
PCA is a method that takes the trajectory of long MD
simulations and calculates the dominant modes in the mo-
tion of the molecule. Thus, the conformational space is
reduced, resulting in few relevant collective degrees of
freedom over which long-range fluctuation can be studied
[36, 37]. PCA diagonalizes the covariance matrix of the
atom fluctuations from their average trajectory. In this
framework, the larger eigenvalues capture the larger fluctu-
ations fraction. The ordering of these eigenvalues gives rise
to a small set of modes that capture most of the protein’s
fluctuation. We performed PCA in order to identify the most
relevant motions occurring in the EGFR family. In this
work, we make use of the first five eigenvectors, which
were projected along the MD trajectory.
Hydrogen bonds (HB) are considered to exist when both
distance between the donor (D) and the acceptor (A) is less
than 0.30 nm and the DHA (hydrogen-donor-acceptor) an-
gle is less than 30°.
The contact maps show the smallest distance between
any pair of atoms belonging to two different residues.
The output is a symmetrical matrix of smallest distances
between all residues. Plotting these matrices for
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different time-frames is a useful tool with which to
analyze changes in the structure, HB networks and
hydrophobic contacts.
The root-mean square fluctuation (RMSF) for each resi-
due was calculated using the g_rmsf tool from GROMACS.
The change in secondary structure elements during the
simulation was monitored using the program DSSP (Define
Secondary Structure of Proteins) [38].
Results and discussion
Comparative homology modeling
Three-dimensional homology models were built for the
ECD of HRGα:ErbB3 and HRGα:ErbB4 complexes,
using as template the X-ray structure corresponding to
chain A of the 2:2 EGF:EGFR dimer (PDB code:
3NJP) [10]. Full alignments of the models are shown
in Supplementary information. The EGFR template has
a high sequence similarity of 41 % and 42 % for the
ErbB3 and ErbB4 proteins, respectively. Cysteine resi-
dues forming disulfide bonds in both receptor and
ligand were well conserved during the alignment pro-
cess. Figure 1 shows the Cα backbone superposition of
the refined HRGα:ErbB3 and HRGα:ErbB4 on the X-
ray structure of the EGF:EGFR. The root mean squared
deviations (RMSD) are 0.8 and 0.7 Å for both ErbB3
and ErbB4 Cα backbones, respectively. As expected, a
high degree of structural similarity was observed due to
the high sequence homology. Furthermore, all second-
ary motifs are well captured as seen in Fig. 1.
a
b
*
*
*
*
Fig. 1 Refined homology
model (a) HRGα(orange):
ErbB3(blue) and (b)
HRGα(orange):ErbB4(blue)
superimposed on the 3NJP
PDB-code X-ray structure EGF
(green):EGFR(red) (PDB code
3NJP). The areas on the right
are enlargements showing
ligand–receptor interactions.
Asterisks mark the ligand loop
with largest deviations between
the target and the homolog
(see text)
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The HRG-α ligand has been modeled using the EGF
structure in the 3NJP complex as template for both ErbB3
and ErbB4 cases. The sequence identity of the EGF template
and HRGα ligand is found to be around 25 %. There are a
couple of NMR-solved structures for HRG-α (PDB code:
1HAF [39] and 1HRF [40]) . However, the EGF ligand in
the 3NJP complex is preferred here over the NMR structure
in solution, because in principle the ligand–protein interac-
tions are better modeled in the 3NJP structure where the
surroundings are taken into account. RMSD values of 3.1
and 3.0 Å were calculated between the EGF Cα backbone
atoms in 3NJP and HRGα in ErbB3 and in ErbB4 homol-
ogy models, respectively. These high values are attributable
to different residues in the region of 1–6 (unbounded loop)
and 23–28 (flexible loop between β-sheet structures) of
EGF and HRG-α ligands (asterisk in the zoomed area of
Fig. 1).
The models were evaluated using Ramachandran
plots calculated by the PROCHECK program. The
percentage occupancies for favored, allowed, generous-
ly allowed and disallowed regions are collected in
Table 1. A percentage of 96.1 and 97.3 % of the
residues are in favored and allowed regions for the
HRG-α:ErbB3 and HRG-α:ErbB4 models, respectively.
After these analyses, the quality of the HRGα:ErbB3
and HRGα:ErbB4 complexes seem to be good enough
for further study.
The homology model of the ErbB2:ErbB3:HRGα
extracellular complex fitted on the X-ray structure of
EGFR:EGF homodimer is shown in Fig. 2. The RMSD
of the Cα backbone atoms are 3.1, 0.8 and 3.0 Å for
ErbB2, ErbB3 and HRGα ligand, respectively. The flex-
ible loop made up of the 70–114 residues in ErbB2 is
causing the high RMSD value (marked with an asterisk
in Fig. 2). This value is reduced to 0.7 Å once the loop
is discarded. Again, the high values of RMSD for the
ligand are attributable to the flexible loops discussed
above. Following the Ramachandran plot, the 95.8 %
of the residues are in favored and allowed regions for
the models. Thus, the ErbB2:ErbB3:HRGα extracellular
complex is good enough for further MD studies.
Molecular dynamics analysis
We have performed MD simulations of each extracellular
system in Table 1 (except for the EGF:EGFR complex) for
at least 100-ns. The aim of these simulations was to study
the stability and the dynamics of the homology models.
Atomistic dynamics of the ErbB2, HRGα:ErbB3
and HRGα:ErbB4 molecules
First, the time evolution of different domain RMSD
(Fig. 3a) was used to track conformational motions along
the trajectory. No global conformational switch from the
extended to the tethered structure was detected in any case.
Thus, the extended conformations remain stable for ErbB2,
HRGα:ErbB3 and HRGα:ErbB4 systems as corresponding
ErbB2 ErbB3 
HRG  
EGFR EGFR 
EGF 
*  
Domain I 
Domain III 
Domain IV 
Domain I 
Domain III 
Domain IV 
Fig. 2 ErbB2:ErbB3:HRGα extracellular heterodimer complex (blue
for ErbB2 and ErbB3 receptors and green for HRG α ligand) using the
(EGFR:EGF)2 homodimer (red and yellow) as template (PDB code
3NJP). The asterisk marks the residues from 70 to 114 (flexible loop)
where the major differences between the target and the homology
model are found
Table 1 Ramachandran plot of HRGα:ErbB3, HRGα:ErbB4 and ErbB2:ErbB4:HRGα homology models calculated with the PROCHECK
software. The 3NJP and 1N8Z x-ray structures are shown as reference. Glycine and proline residues are not taken into account
EGF:EGFRa ErbB2b HRGα:ErbB3 HRGα:ErbB4 ErbB2/ErbB3:HRGα
% in most favored regions 78.2 82.6 72.2 72.5 72.3
% in additional allowed regions 19.9 15.3 23.9 24.8 23.5
% in generously allowed regions 1.1 2.0 2.7 1.2 2.7
% in disallowed regions 0.8 0.0 1.3 1.5 1.5
a Chain A of the X-ray structure reported in the 3NJP pdb file
b Chain C of the X-ray structure reported in the 1N8Z pdb file
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to active states. Domains I and III remain stable along the
whole trajectory to values smaller than 2 Å from the crystal
structure (ErbB2) or homology models (HRGα:ErbB3 and
HRGα:ErbB4). Domains II and IV for ErbB2 are stable
with respect to the reference crystal structure, showing only
a small deviation of around 3 Å. On the contrary, domains II
and IV for the HRGα:ErbB3 and HRGα:ErbB4 receptors
exhibit deviations in the range of 4–7 and 6–10 Å, respec-
tively. The RMSD profiles for HRGα:ErbB3 and HRGα:
ErbB4 complexes are similar, but the domain II deviations,
which are larger for HRGα:ErbB4 (7 Å versus 4–5 Å, blue
lines in Fig. 3a), point to a more movable dimerization arm.
In summary, the largest deviations were observed for
homology-based structures along the MD trajectories.
Additionally, some remarkable residue moves were ob-
served through RMSF analysis. As shown in Fig. 3, the intense
peak observed in domain I (peak I) for ErbB2 corresponds to
the motion of a flexible loop (N124–A132). On the contrary, this
loop becomes more constrained in ErbB3 and ErbB4 proteins
as a consequence of the presence of the HRGα ligand. It should
be noted that this loop has not been solved experimentally for
the ErbB2 extracellular domain by X-ray techniques, suggest-
ing that the loop is very flexible in that protein [8]. The
dimerization arm residues exhibit high RMSF values for all
proteins (peak II in Fig. 3), showing a periscope-like motion
[18]. This motion can assist the formation of dimers between
different members of the EGFR family. Finally, domain IV is
very mobile with the highest RMSF values (peak III) in all
Fig. 3 a Root mean square deviation (RMSD) of the different domains
as a function of time for ErbB2 (top), HRGα:ErbB3 (middle) and
HRGα:ErbB4 (bottom) systems. Domains I, II, III and IV are shown
as green, blue, magenta and red lines, respectively. b Root-mean
square fluctuation (RMSF) as a function of the residue number in
backbone atoms. The monomers ErbB2 (top), HRGα:ErbB3 (middle)
and HRGα:ErbB4 (bottom) are shown as red lines. The blue lines
corresponds to ErbB2 and HRGα:ErbB3 in the heterodimer complex.
Roman numbers are used to number the most important peaks. The last
50 ns of the trajectory were taken in all cases
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cases for the proteins alone, corresponding to a hinge motion
within this domain. This flexibility could explain the difficulty
encountered by other studies in elucidating domain IV by
crystallographic techniques on the extended conformations of
protein monomers [7, 8]. Although domain II is very flexible in
all members of the EGFR family, inspection of both trajectory
and RMSD values suggests that ErbB4 is the most flexible.
Let us focus now our analysis on the slowest modes that
could provide information on the collective motions of EGFR
domains. PCA was performed on the Cα atoms for the three
molecules. Despite the fact that PCA was calculated for a
single trajectory, some useful qualitative information can be
extracted from this analysis. The first three eigenvectors ac-
count for ca. 80 % of the motion in ErbB2, HRGα:ErbB3 and
Fig. 5 RMSD of the domains
as a function of time for ErbB2
(top) and HRGα:ErbB3
(bottom) systems in the
heterodimer complex. Domains
I, II, III and IV are shown as
green, blue, magenta and red
lines, respectively
Eigenvalue 2Eigenvalue1 Eigenvalue 3
Dimerization
arm
Domain IV
Domain I
Domain
III
Domain II
Fig. 4 Dominant motions represented by the first three principal
component analysis (PCA) eigenvectors in EGFR systems. Several
projections are shown in different colors between the two extreme
points(blue and red colors). Arrows indicate the direction of motion
along the molecular dynamics (MD) simulation for each eigenvector.
This figure shows the eigenvectors on the ErbB2 molecule. Eigenvec-
tors for the HRGα:ErbB3 and HRGα:ErbB4 systems are similar, so are
shown in separate Figures in the Supplementary information section
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HRGα:ErbB4 molecules, respectively. The principal motions
for the first three eigenvectors of the ErbB2 molecule are
shown in Fig. 4 (for ErbB3 and ErbB4 the motions are shown
as Supplementary information because they are similar. The
corresponding videos are available as Supplementary infor-
mation). A concerted hinge movement of domain IV is ob-
served clearly for the first PCA eigenvector. The other two
eigenvectors show clockwise and counterclockwise torsions
of domains II and IV, respectively. Thus, PCA analysis con-
firms that domains II and IV are very flexible, in agreement
with the previous discussion.
Summarizing, MD analysis of the free EGFRs led to the
conclusion that great flexibility of domains II and IV exists
in the extended structures. It could be hypothesized that this
intrinsic flexibility would increase the possibility of forming
dimers among different members of the EGFR family.
Atomistic dynamics of the back-to-back ErbB2:ErbB3:
HRGα complex
Global conformation dynamics The homology model for
the ErbB2:ErbB3:HRGα heterodimer is shown in Fig. 2.
We used this model as the initial structure for a 100 ns MD
simulation. The overall change in conformation of the het-
erodimer from the homology structure can be tracked by
plotting the RMSD of each domain (Fig. 5). All domains in
the monomers remain stable within less than 0.4 nm from
the homology model and they all relax over the first 10 ns.
The exception is domain II in ErbB3, which has higher
RMSD values (ca. 0.6 nm) and large fluctuations, even at
the end of the simulation. Moreover, the flexibility of each
domain of the heterodimer was quantified by calculating the
RMSF for Cα atoms in each residue (Fig. 3b). The fluctua-
tions in domains II and IV (peaks II and III) are reduced in
the heterodimer (blue lines in Fig. 3b) as compared to the
free monomers (red lines in Fig. 3b). Therefore, as expected,
interactions between the dimerization arms (domain II) and
domain IV of both ErbB2 and ErbB3 monomers reduce the
flexibility of such domains in the heterodimer.
Intermolecular dimerization interfaces Experimentally, the
crystal structure of the (EGFR:EGF)2 homodimer is mediated
by intermolecular interactions involving both the dimerization
arm in domain II [6, 7, 10] and the C terminus located at
domain IV [10]. In the present case, the dimerization arm in
domain II of any monomer (i.e., ErbB2) tends to interact with
a region between domains I and II of the neighboring receptor.
Interactions between residues placed at domain IV are also
observed (see Fig. 2). The most important non-bonded close
contacts between the ErbB2 and ErbB3 are collected in
Table 2. These contacts take into account salt bridges, HBs,
aromatic interactions and hydrophobic contacts. As it can be
seen in Table 2, the domain II–domain II interface is made up
of both hydrophobic and HB interactions in which the 15-
residue dimerization arms go through the pocket region of
domains I and II of the neighboring receptor. However, a
persistent interaction with domain III of ErbB2 was observed
only for the ErbB3 dimerization arm. The domain IV–domain
IV interfaces are shown in Fig. 6. As can be seen, two regions
are kept from the last 50 ns of the trajectory. The first region
(Fig. 6b) corresponds to residues A599–L609 and S587–E596 in
ErbB2 and ErbB3, respectively. This region has a marked
hydrophobic character with residues P602 and V605 in the
ErbB2 receptor and P590, V593 and L594 in the ErbB3 receptor.
On the other hand, the second region (Fig. 6c) corresponds to
residues C631–C635 and C617–G623 in ErbB2 and ErbB3,
Table 2 Interface non-bonded close contacts (salt bridges, H-bonds,
aromatic and hydrophobic interactions) in the ErbB2:ErbB3:HRGα
complex. The domain to which each amino acid belongs is given in
parentheses. Only residue–residue contacts with averaged contact area
above 20 Å2 are displayed. The H-bonds reported fulfill the criteria that
the donor–acceptor distance and angle cutoffs of 3.5 Å and 30° are
maintained during at least 50 % of the last 50 ns of the trajectory. The
distance in salt bridges is less than 4.0 Å
ErbB2 ErbB3 Interaction type
Dimerization
ErbB2 arma
V273(II) R258(II) Hydrophobic
Y275(II) C301(II) H-bond
D278(II) T108(I) Hydrophobic
F280(II) R267(II),
Y282(II)
Hydrophobic,
aromatic
E281(II) A304(II) Hydrophobic
Dimerization
ErbB3 armb
T291(II),
C312(III)
Y265(II) Hydrophobic,
H-bonds
H258(II) K267(II) Hydrophobic
Q58(I) L268(II) H-bonds
F292(II),
Y304(II)
F270(II) Hydrophobic,
aromatic
L314(III) Q271(II) Hydrophobic
T313(III) L272(II) Not assigned
Domain II -
Domain IIc
G224(II) N224(II) H-bond
P233(II) Q213(II) H-bond
K333(II) E321(II) Salt bridge
R352(II) E273(II) Salt bridge
Domain IV -
Domain IVd
P602 (IV),
V605(IV)
P590(IV),
V593(IV),
L594(IV)
Hydrophobic
H633(IV) C621(IV) H-bond
A645(IV) L622(IV) H-bond
a Interaction between residues at the dimerization arm of the ErbB2
with the ErbB3 receptor. The arm dimerization in ErbB2 receptor is
defined as residues 271–286
b Interaction between residues at the dimerization arm of the ErbB3
with the ErbB2 receptor. The arm dimerization in ErbB3 receptor is
defined as residues 261–276
c Persistent hydrogen bonds between residues belonging to domain II
d Persistent contacts between residues located at domain IV
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respectively. In this case, the interaction is maintained by the
formation of two hydrogen bonds (see Table 2).
PCAwas carried out on the MD trajectory to identify the
most significant cooperative motions of the ErbB2:ErbB3:
HRGα complex. The first three eigenvectors account for
75 % of the overall motions. These three eigenvectors
consist mainly of concerted motions of both domains IV
(not shown). Remarkably, the motion of domain II is more
constrained in comparison with the ErbB2 and ErbB3 free
receptors.
Conclusions
The present work provides a useful collection of homology
models for the ECD ErbB receptors updated with the infor-
mation provided by the latest crystallographic structures of
suitable templates deposited with the Protein Data Bank. In
particular, the model for ErbB3 and ErbB4 receptors
includes the structure of domain IV which was absent in
previous studies. The quality of the models is proved to be
very satisfactory in view of the resulting RMSD differences
with the template structures and Ramachandran maps show-
ing suitable backbone torsion angle distributions.
These models were subsequently refined by MD simula-
tion. It is worth mentioning that, according to the RMSD
time evolution, the ErbB2 receptor, built from crystallo-
graphic data, exhibits the most stable structure along the
whole simulation. A set of common features was found for
all the receptors, namely a periscope movement of the
dimerization arm in domain II, which confirms the findings
of previous studies. What is more important is the remark-
able flexibility found for domain IV. A hinge movement of
this domain towards domains II and III was observed in all
cases. In this context, PCA reveals that the first eigenvectors
are associated to this collective movement.
We have also proposed a model for the interaction of
ErbB2 and ErbB3. This complex forms one of the most
biologically relevant heterodimers associated with aggres-
sive carcinomas. To the best of our knowledge, the model
proposed in our work is the first atomistic scale model for
ECD interaction in this heterodimer. The structure presents
the expected interaction between the two receptors through
the dimerization arms in domain II, which immobilizes
these domains with respect to the unbound structures. In
addition to this, a weaker interaction through domain IV is
also observed. However, the hinge movement observed in
the separated receptors is also noticeable in the complex in
an asymmetric way, being less mobile in ErbB2 than in
ErbB3.
The biological consequences of this information are not
so evident, and further studies need to be carried out.
Contact region I
Contact region II
a
b
c
P590
L594 V
593 
H 633
C602
Fig. 6 a Domain IV–domain
IV interface. Interactions in
region defined as I (b) and II (c)
are zoomed. White surfaces
Hydrophobic contacts, green
surfaces polar contacts. The
main residues responsible for
each interaction are labeled
inside the figure. ErbB2 and
ErbB3 receptors are shown as
blue and red cartoon models
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However, the generation of the ECD ErbBs models pre-
sented in this work will serve as an starting point for a
systematic study of these important receptors in order to
provide clues for the development of more effective thera-
peutic strategies.
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